CompletedPhase 2NCT00612430

Ph II Bevacizumab + Etoposide for Pts w Recurrent MG

Studying Glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Duke University
Principal Investigator
David A. Reardon, MD
Duke Health
Intervention
Bevacizumab and Etoposide(drug)
Enrollment
59 enrolled
Eligibility
18 years · All sexes
Timeline
20072011

Study locations (1)

Collaborators

Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00612430 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma

← Back to all trials